Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis

Genetics and Molecular Biology

Volumn 35, Issue 4 SUPPL., 2012, Pages 947-954

  Alegra, Taciane ^a   Vairo, Filippo ^a,b   de Souza, Monica V ^a   Krug, Bárbara C ^a   Schwartz, Ida V D ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Alpha Galactosidase; Enzyme replacement therapy; Fabry disease; Fabry disease therapy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; CREATININE; GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO;

ADOLESCENT; ADULT; BLOOD LEVEL; CHILL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FABRY DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTENSION; HYPOTENSION; LARYNX EDEMA; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PAIN; PATIENT SELECTION; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; REVIEW; RIGOR; SAMPLE SIZE; SYSTEMATIC REVIEW; THORAX PAIN; URTICARIA; VOMITING;

EID: 84872458046     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572012000600009     Document Type: Review

References (30)

1. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146:77-86.
2. Bierer G, Balfe D, Wilcox WR and Mosenifar Z (2006) Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 29:572-579.
3. Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A and Aerts JM (2003) Recombinant enzyme therapy for Fabry disease: Absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 72:23-31.
4. Bradburn MJ, Deeks JJ, Berlin JA and Russell Localio A (2007) Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Stat Med 15:26:53-77.
5. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A and Moore D (2006) A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 10:iii-iv, ix-113.
6. Desnick RJ, Ioannou YA and Eng CM (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE and Vogelstein B (eds) The Metabolic and Molecular Bases of Inherited Diseases. 8th edition. McGraw-Hill, New York, pp 3733-3774.
7. DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
8. El Dib RP and Pastores GM (2010) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev CD006663.
9. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE and Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. NEngl J Med 345:9-16.
10. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, et al. (2007) Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184-192.
11. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J and Mehta AB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153-158.
12. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, et al. (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305-313.
13. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R and Papo T (2007) Clinical results of enzyme replacement therapy in Fabry disease: A comprehensive review of literature. Int J Clin Pract 61:293-302.
14. Meikle PJ, Hopwood JJ, Clague AE and Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249-254.
15. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: Reversal by enzyme replacement therapy. Circulation 104:1506-1512.
16. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, et al. (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525-531.
17. Pieroni M, Chimenti C, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, Russo MA and Frustaci A (2006) Fabry's disease cardiomyopathy: Echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47:1663-1671.
18. Pinto LL, Vieira TA, Giugliani R and Schwartz IV (2010) Expression of the disease on female carriers of X-linked lysosomal disorders: A brief review. Orphanet J Rare Dis 5:14.
19. Politei JM and Capizzano AA (2006) Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist 12:103-105.
20. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T, et al. (2005) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51:180-188.
21. Schaefer RM, Tylki-Szymanska A and Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: A systematic review of available evidence. Drugs 69:2179-2205.
22. Schiffmann R, Kopp JB, Austin 3rd HA, Sabnis S, Moore DF, Weibel T, Balow JE and Brady RO (2001) Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285:2743-2749.
23. Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC and Wagner K (2006) Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 34:53-56.
24. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A and Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31-40.
25. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ and O'Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933-1946.
26. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE and O'Callaghan M (2004) Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122:900-908.
27. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A and Hollak CE (2007) Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2:e598.
28. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, et al. (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 93:112-128.
29. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J and Taylor RS (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 9:1-179, iii-iv.
30. Wraith JE. 2004. Clinical aspects and diagnosis. In: Platt FM and Walkley SU (eds) Lysosomal Disorders of the Brain. Oxford University Press, Oxford, pp 50-80.